KR20200116546A - 태반 줄기 세포를 이용하는 척수 손상 및 외상성 뇌 손상의 치료 - Google Patents
태반 줄기 세포를 이용하는 척수 손상 및 외상성 뇌 손상의 치료 Download PDFInfo
- Publication number
- KR20200116546A KR20200116546A KR1020207027962A KR20207027962A KR20200116546A KR 20200116546 A KR20200116546 A KR 20200116546A KR 1020207027962 A KR1020207027962 A KR 1020207027962A KR 20207027962 A KR20207027962 A KR 20207027962A KR 20200116546 A KR20200116546 A KR 20200116546A
- Authority
- KR
- South Korea
- Prior art keywords
- cells
- placental
- isolated
- stem cells
- population
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000004991 placental stem cell Anatomy 0.000 title claims abstract description 299
- 208000020431 spinal cord injury Diseases 0.000 title claims abstract description 136
- 208000030886 Traumatic Brain injury Diseases 0.000 title claims abstract description 100
- 230000009529 traumatic brain injury Effects 0.000 title claims abstract description 100
- 238000011282 treatment Methods 0.000 title description 50
- 238000000034 method Methods 0.000 claims abstract description 188
- 208000024891 symptom Diseases 0.000 claims description 97
- 230000006872 improvement Effects 0.000 claims description 51
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 35
- 208000035475 disorder Diseases 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 17
- 230000001143 conditioned effect Effects 0.000 claims description 13
- 239000001963 growth medium Substances 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 abstract description 927
- 230000003169 placental effect Effects 0.000 abstract description 548
- 230000006378 damage Effects 0.000 abstract description 123
- 210000003169 central nervous system Anatomy 0.000 abstract description 52
- 210000001778 pluripotent stem cell Anatomy 0.000 abstract description 2
- 102100037241 Endoglin Human genes 0.000 description 125
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 125
- 210000002826 placenta Anatomy 0.000 description 117
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 115
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 115
- 101001098352 Homo sapiens OX-2 membrane glycoprotein Proteins 0.000 description 107
- 102100037589 OX-2 membrane glycoprotein Human genes 0.000 description 107
- 210000000130 stem cell Anatomy 0.000 description 105
- 102100022464 5'-nucleotidase Human genes 0.000 description 98
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 98
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 96
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 96
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 92
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 90
- 208000014674 injury Diseases 0.000 description 86
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 76
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 76
- 208000027418 Wounds and injury Diseases 0.000 description 76
- 239000000203 mixture Substances 0.000 description 74
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 67
- 108010024164 HLA-G Antigens Proteins 0.000 description 67
- 108090000028 Neprilysin Proteins 0.000 description 59
- 102000003729 Neprilysin Human genes 0.000 description 59
- 230000010412 perfusion Effects 0.000 description 50
- 230000033001 locomotion Effects 0.000 description 46
- 210000001744 T-lymphocyte Anatomy 0.000 description 44
- 230000004044 response Effects 0.000 description 44
- 210000002865 immune cell Anatomy 0.000 description 36
- 239000000243 solution Substances 0.000 description 35
- 230000000694 effects Effects 0.000 description 33
- 102100032912 CD44 antigen Human genes 0.000 description 32
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 32
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 32
- 210000003205 muscle Anatomy 0.000 description 31
- 210000001519 tissue Anatomy 0.000 description 31
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 30
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 30
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 30
- 230000014509 gene expression Effects 0.000 description 30
- 238000012216 screening Methods 0.000 description 30
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 29
- 102100025304 Integrin beta-1 Human genes 0.000 description 29
- 230000007423 decrease Effects 0.000 description 29
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 29
- 239000003814 drug Substances 0.000 description 27
- 230000001464 adherent effect Effects 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 26
- 230000001506 immunosuppresive effect Effects 0.000 description 25
- 210000000278 spinal cord Anatomy 0.000 description 25
- 238000003556 assay Methods 0.000 description 24
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 description 23
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 23
- 229940124597 therapeutic agent Drugs 0.000 description 23
- 230000015572 biosynthetic process Effects 0.000 description 22
- -1 CD86 Proteins 0.000 description 20
- 230000006052 T cell proliferation Effects 0.000 description 20
- 230000033115 angiogenesis Effects 0.000 description 20
- 210000004700 fetal blood Anatomy 0.000 description 20
- 208000011580 syndromic disease Diseases 0.000 description 20
- 230000007659 motor function Effects 0.000 description 19
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 18
- 210000001185 bone marrow Anatomy 0.000 description 18
- 230000028993 immune response Effects 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 17
- 238000001727 in vivo Methods 0.000 description 17
- 239000003550 marker Substances 0.000 description 17
- 230000002401 inhibitory effect Effects 0.000 description 16
- 230000001605 fetal effect Effects 0.000 description 15
- 210000002540 macrophage Anatomy 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- 230000037152 sensory function Effects 0.000 description 15
- 239000000758 substrate Substances 0.000 description 15
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 14
- 102000003814 Interleukin-10 Human genes 0.000 description 14
- 108090000174 Interleukin-10 Proteins 0.000 description 14
- 208000002193 Pain Diseases 0.000 description 14
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 14
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 14
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 229940088598 enzyme Drugs 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 14
- 229940076144 interleukin-10 Drugs 0.000 description 14
- 230000035755 proliferation Effects 0.000 description 14
- 210000002889 endothelial cell Anatomy 0.000 description 13
- 210000004993 mammalian placenta Anatomy 0.000 description 13
- 230000008774 maternal effect Effects 0.000 description 13
- 102100022749 Aminopeptidase N Human genes 0.000 description 12
- 206010010254 Concussion Diseases 0.000 description 12
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 12
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 12
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 12
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 12
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 12
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 12
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 12
- 230000009118 appropriate response Effects 0.000 description 12
- 230000006399 behavior Effects 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 230000009514 concussion Effects 0.000 description 12
- 210000004443 dendritic cell Anatomy 0.000 description 12
- 230000005484 gravity Effects 0.000 description 12
- 230000002519 immonomodulatory effect Effects 0.000 description 12
- 230000009467 reduction Effects 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 108010074708 B7-H1 Antigen Proteins 0.000 description 11
- 102000004889 Interleukin-6 Human genes 0.000 description 11
- 108090001005 Interleukin-6 Proteins 0.000 description 11
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 11
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 11
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 11
- 238000007917 intracranial administration Methods 0.000 description 11
- 210000005036 nerve Anatomy 0.000 description 11
- 230000036407 pain Effects 0.000 description 11
- 210000003606 umbilical vein Anatomy 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 10
- 108010075704 HLA-A Antigens Proteins 0.000 description 10
- 101000629400 Homo sapiens Mesoderm-specific transcript homolog protein Proteins 0.000 description 10
- 206010062016 Immunosuppression Diseases 0.000 description 10
- 102100026821 Mesoderm-specific transcript homolog protein Human genes 0.000 description 10
- 108090000631 Trypsin Proteins 0.000 description 10
- 102000004142 Trypsin Human genes 0.000 description 10
- 208000003443 Unconsciousness Diseases 0.000 description 10
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 10
- 230000003935 attention Effects 0.000 description 10
- 230000019771 cognition Effects 0.000 description 10
- 238000012258 culturing Methods 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 229940100601 interleukin-6 Drugs 0.000 description 10
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 10
- 210000005059 placental tissue Anatomy 0.000 description 10
- 230000011514 reflex Effects 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 10
- 239000012588 trypsin Substances 0.000 description 10
- 102100021597 Endoplasmic reticulum aminopeptidase 2 Human genes 0.000 description 9
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 description 9
- 230000003110 anti-inflammatory effect Effects 0.000 description 9
- 239000003146 anticoagulant agent Substances 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 230000006862 enzymatic digestion Effects 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 9
- 238000011084 recovery Methods 0.000 description 9
- 210000001644 umbilical artery Anatomy 0.000 description 9
- 210000003954 umbilical cord Anatomy 0.000 description 9
- 230000002792 vascular Effects 0.000 description 9
- 206010010904 Convulsion Diseases 0.000 description 8
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 8
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 8
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 8
- 101000998020 Homo sapiens Keratin, type I cytoskeletal 18 Proteins 0.000 description 8
- 102000004890 Interleukin-8 Human genes 0.000 description 8
- 108090001007 Interleukin-8 Proteins 0.000 description 8
- 238000011374 additional therapy Methods 0.000 description 8
- 229940127219 anticoagulant drug Drugs 0.000 description 8
- 210000001136 chorion Anatomy 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 229940096397 interleukin-8 Drugs 0.000 description 8
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 8
- 108010080821 leucine-rich amelogenin peptide Proteins 0.000 description 8
- 229920003023 plastic Polymers 0.000 description 8
- 239000004033 plastic Substances 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 230000001953 sensory effect Effects 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 7
- 102000000905 Cadherin Human genes 0.000 description 7
- 108050007957 Cadherin Proteins 0.000 description 7
- 102100021598 Endoplasmic reticulum aminopeptidase 1 Human genes 0.000 description 7
- 102000015789 HLA-DP Antigens Human genes 0.000 description 7
- 108010010378 HLA-DP Antigens Proteins 0.000 description 7
- 208000032843 Hemorrhage Diseases 0.000 description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
- 201000007201 aphasia Diseases 0.000 description 7
- 230000000740 bleeding effect Effects 0.000 description 7
- 230000006735 deficit Effects 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 208000002173 dizziness Diseases 0.000 description 7
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 7
- 229920000669 heparin Polymers 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 239000003018 immunosuppressive agent Substances 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000008449 language Effects 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000008733 trauma Effects 0.000 description 7
- 210000003932 urinary bladder Anatomy 0.000 description 7
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 6
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 6
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 6
- 108060005980 Collagenase Proteins 0.000 description 6
- 102000029816 Collagenase Human genes 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 101710168245 Endoplasmic reticulum aminopeptidase 1 Proteins 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 241001494479 Pecora Species 0.000 description 6
- 238000010240 RT-PCR analysis Methods 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 210000001691 amnion Anatomy 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 210000001508 eye Anatomy 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 229960002897 heparin Drugs 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 210000003141 lower extremity Anatomy 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 6
- 208000000044 Amnesia Diseases 0.000 description 5
- 102100023471 E-selectin Human genes 0.000 description 5
- 101000622123 Homo sapiens E-selectin Proteins 0.000 description 5
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 5
- 101000588303 Homo sapiens Nuclear factor erythroid 2-related factor 3 Proteins 0.000 description 5
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 5
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 5
- 102100033467 L-selectin Human genes 0.000 description 5
- 206010027951 Mood swings Diseases 0.000 description 5
- 102100031700 Nuclear factor erythroid 2-related factor 3 Human genes 0.000 description 5
- 102100023472 P-selectin Human genes 0.000 description 5
- 206010033799 Paralysis Diseases 0.000 description 5
- 206010037714 Quadriplegia Diseases 0.000 description 5
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 5
- 239000002870 angiogenesis inducing agent Substances 0.000 description 5
- 230000002491 angiogenic effect Effects 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 210000000133 brain stem Anatomy 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 229960002424 collagenase Drugs 0.000 description 5
- 230000006835 compression Effects 0.000 description 5
- 238000007906 compression Methods 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 210000003414 extremity Anatomy 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 229960003444 immunosuppressant agent Drugs 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 238000007914 intraventricular administration Methods 0.000 description 5
- 231100000878 neurological injury Toxicity 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 230000035939 shock Effects 0.000 description 5
- 206010002653 Anosmia Diseases 0.000 description 4
- 208000006569 Central Cord Syndrome Diseases 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 206010010071 Coma Diseases 0.000 description 4
- 208000003164 Diplopia Diseases 0.000 description 4
- 101800003838 Epidermal growth factor Proteins 0.000 description 4
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 208000001953 Hypotension Diseases 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 102000013462 Interleukin-12 Human genes 0.000 description 4
- 108010065805 Interleukin-12 Proteins 0.000 description 4
- 102000003810 Interleukin-18 Human genes 0.000 description 4
- 108090000171 Interleukin-18 Proteins 0.000 description 4
- 102000013264 Interleukin-23 Human genes 0.000 description 4
- 108010065637 Interleukin-23 Proteins 0.000 description 4
- 206010022998 Irritability Diseases 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 208000026139 Memory disease Diseases 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 4
- 206010058119 Neurogenic shock Diseases 0.000 description 4
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 102000012479 Serine Proteases Human genes 0.000 description 4
- 108010022999 Serine Proteases Proteins 0.000 description 4
- 206010065954 Stubbornness Diseases 0.000 description 4
- 208000009205 Tinnitus Diseases 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 230000016571 aggressive behavior Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 4
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 239000003636 conditioned culture medium Substances 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 108010007093 dispase Proteins 0.000 description 4
- 208000029444 double vision Diseases 0.000 description 4
- 229940116977 epidermal growth factor Drugs 0.000 description 4
- 229940126864 fibroblast growth factor Drugs 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical class OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 4
- 230000036543 hypotension Effects 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 230000006057 immunotolerant effect Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 108010074108 interleukin-21 Proteins 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000015654 memory Effects 0.000 description 4
- 230000006984 memory degeneration Effects 0.000 description 4
- 208000023060 memory loss Diseases 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 230000000926 neurological effect Effects 0.000 description 4
- 230000008447 perception Effects 0.000 description 4
- 229920000371 poly(diallyldimethylammonium chloride) polymer Polymers 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 210000003289 regulatory T cell Anatomy 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 208000019116 sleep disease Diseases 0.000 description 4
- 208000022925 sleep disturbance Diseases 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 210000000115 thoracic cavity Anatomy 0.000 description 4
- 231100000886 tinnitus Toxicity 0.000 description 4
- 230000000472 traumatic effect Effects 0.000 description 4
- 230000024883 vasodilation Effects 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 230000004393 visual impairment Effects 0.000 description 4
- 102100022454 Actin, gamma-enteric smooth muscle Human genes 0.000 description 3
- 102100040023 Adhesion G-protein coupled receptor G6 Human genes 0.000 description 3
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 3
- 102100029229 Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 5 Human genes 0.000 description 3
- 102100032040 Amphoterin-induced protein 2 Human genes 0.000 description 3
- 108090000145 Bacillolysin Proteins 0.000 description 3
- 108010081589 Becaplermin Proteins 0.000 description 3
- 102100027386 Beta-1,4-galactosyltransferase 6 Human genes 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 description 3
- 208000007774 Broca Aphasia Diseases 0.000 description 3
- 102100035793 CD83 antigen Human genes 0.000 description 3
- 102100030621 Carboxypeptidase A4 Human genes 0.000 description 3
- 102000001326 Chemokine CCL4 Human genes 0.000 description 3
- 108010055165 Chemokine CCL4 Proteins 0.000 description 3
- 102100032404 Cholinesterase Human genes 0.000 description 3
- 102100022145 Collagen alpha-1(IV) chain Human genes 0.000 description 3
- 102100033781 Collagen alpha-2(IV) chain Human genes 0.000 description 3
- 102000016911 Deoxyribonucleases Human genes 0.000 description 3
- 108010053770 Deoxyribonucleases Proteins 0.000 description 3
- 102100037709 Desmocollin-3 Human genes 0.000 description 3
- 102100034578 Desmoglein-2 Human genes 0.000 description 3
- 102100038191 Double-stranded RNA-specific editase 1 Human genes 0.000 description 3
- 102100023882 Endoribonuclease ZC3H12A Human genes 0.000 description 3
- 102100031375 Endothelial lipase Human genes 0.000 description 3
- 102000003951 Erythropoietin Human genes 0.000 description 3
- 108090000394 Erythropoietin Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 102100037362 Fibronectin Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 229920001917 Ficoll Polymers 0.000 description 3
- 102100032523 G-protein coupled receptor family C group 5 member B Human genes 0.000 description 3
- 101000678433 Homo sapiens Actin, gamma-enteric smooth muscle Proteins 0.000 description 3
- 101000959602 Homo sapiens Adhesion G-protein coupled receptor G6 Proteins 0.000 description 3
- 101000776165 Homo sapiens Amphoterin-induced protein 2 Proteins 0.000 description 3
- 101000937502 Homo sapiens Beta-1,4-galactosyltransferase 6 Proteins 0.000 description 3
- 101000823298 Homo sapiens Broad substrate specificity ATP-binding cassette transporter ABCG2 Proteins 0.000 description 3
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 3
- 101000772572 Homo sapiens Carboxypeptidase A4 Proteins 0.000 description 3
- 101000943274 Homo sapiens Cholinesterase Proteins 0.000 description 3
- 101000901150 Homo sapiens Collagen alpha-1(IV) chain Proteins 0.000 description 3
- 101000710876 Homo sapiens Collagen alpha-2(IV) chain Proteins 0.000 description 3
- 101000968042 Homo sapiens Desmocollin-2 Proteins 0.000 description 3
- 101000880960 Homo sapiens Desmocollin-3 Proteins 0.000 description 3
- 101000924314 Homo sapiens Desmoglein-2 Proteins 0.000 description 3
- 101000742223 Homo sapiens Double-stranded RNA-specific editase 1 Proteins 0.000 description 3
- 101000976212 Homo sapiens Endoribonuclease ZC3H12A Proteins 0.000 description 3
- 101000941275 Homo sapiens Endothelial lipase Proteins 0.000 description 3
- 101001014684 Homo sapiens G-protein coupled receptor family C group 5 member B Proteins 0.000 description 3
- 101000840577 Homo sapiens Insulin-like growth factor-binding protein 7 Proteins 0.000 description 3
- 101000582994 Homo sapiens Myelin regulatory factor Proteins 0.000 description 3
- 101001094807 Homo sapiens Paraneoplastic antigen-like protein 8A Proteins 0.000 description 3
- 101001098560 Homo sapiens Proteinase-activated receptor 2 Proteins 0.000 description 3
- 101000735377 Homo sapiens Protocadherin-7 Proteins 0.000 description 3
- 101000823237 Homo sapiens Reticulon-1 Proteins 0.000 description 3
- 101000836075 Homo sapiens Serpin B9 Proteins 0.000 description 3
- 101000800546 Homo sapiens Transcription factor 21 Proteins 0.000 description 3
- 101000819088 Homo sapiens Transcription factor GATA-6 Proteins 0.000 description 3
- 101000836755 Homo sapiens Type 2 lactosamine alpha-2,3-sialyltransferase Proteins 0.000 description 3
- 108010003272 Hyaluronate lyase Proteins 0.000 description 3
- 102000001974 Hyaluronidases Human genes 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
- 102100029228 Insulin-like growth factor-binding protein 7 Human genes 0.000 description 3
- 102100022341 Integrin alpha-E Human genes 0.000 description 3
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108050003558 Interleukin-17 Proteins 0.000 description 3
- 102000013691 Interleukin-17 Human genes 0.000 description 3
- 102100030703 Interleukin-22 Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108010072582 Matrilin Proteins Proteins 0.000 description 3
- 102100033669 Matrilin-2 Human genes 0.000 description 3
- 102000005741 Metalloproteases Human genes 0.000 description 3
- 108010006035 Metalloproteases Proteins 0.000 description 3
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 3
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 3
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 3
- 102100030372 Myelin regulatory factor Human genes 0.000 description 3
- 102000035092 Neutral proteases Human genes 0.000 description 3
- 108091005507 Neutral proteases Proteins 0.000 description 3
- 108010067372 Pancreatic elastase Proteins 0.000 description 3
- 102000016387 Pancreatic elastase Human genes 0.000 description 3
- 102100035458 Paraneoplastic antigen-like protein 8A Human genes 0.000 description 3
- 206010033892 Paraplegia Diseases 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 102100037132 Proteinase-activated receptor 2 Human genes 0.000 description 3
- 102100034941 Protocadherin-7 Human genes 0.000 description 3
- 102100022647 Reticulon-1 Human genes 0.000 description 3
- 108091006628 SLC12A8 Proteins 0.000 description 3
- 108010069296 ST6GalNAc V brain-specific GD1alpha synthase Proteins 0.000 description 3
- 102100025517 Serpin B9 Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 102100036751 Solute carrier family 12 member 8 Human genes 0.000 description 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 3
- 210000000447 Th1 cell Anatomy 0.000 description 3
- 102100033121 Transcription factor 21 Human genes 0.000 description 3
- 102100021382 Transcription factor GATA-6 Human genes 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 102100027107 Type 2 lactosamine alpha-2,3-sialyltransferase Human genes 0.000 description 3
- 206010047513 Vision blurred Diseases 0.000 description 3
- 102100035140 Vitronectin Human genes 0.000 description 3
- 208000002579 Wernicke Aphasia Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 229960002576 amiloride Drugs 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000002567 autonomic effect Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000002771 cell marker Substances 0.000 description 3
- 239000002458 cell surface marker Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 206010013932 dyslexia Diseases 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 230000002996 emotional effect Effects 0.000 description 3
- 229940105423 erythropoietin Drugs 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 210000001652 frontal lobe Anatomy 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 229960002773 hyaluronidase Drugs 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 230000001146 hypoxic effect Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 238000001361 intraarterial administration Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000007919 intrasynovial administration Methods 0.000 description 3
- 238000007913 intrathecal administration Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000002414 leg Anatomy 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000003041 ligament Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000037230 mobility Effects 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 239000004090 neuroprotective agent Substances 0.000 description 3
- 210000000869 occipital lobe Anatomy 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 210000001152 parietal lobe Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 235000019615 sensations Nutrition 0.000 description 3
- 229960002930 sirolimus Drugs 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 206010041569 spinal fracture Diseases 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000002889 sympathetic effect Effects 0.000 description 3
- 229960001967 tacrolimus Drugs 0.000 description 3
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 3
- 210000003478 temporal lobe Anatomy 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 2
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 2
- 206010001488 Aggression Diseases 0.000 description 2
- 206010002942 Apathy Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 2
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 2
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 2
- 206010056948 Automatic bladder Diseases 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 101100294106 Caenorhabditis elegans nhr-3 gene Proteins 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 102100024108 Dystrophin Human genes 0.000 description 2
- 102100032050 Elongation of very long chain fatty acids protein 2 Human genes 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 208000036993 Frustration Diseases 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 108010024636 Glutathione Chemical class 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- 102000007625 Hirudins Human genes 0.000 description 2
- 108010007267 Hirudins Proteins 0.000 description 2
- 101001053946 Homo sapiens Dystrophin Proteins 0.000 description 2
- 101000921368 Homo sapiens Elongation of very long chain fatty acids protein 2 Proteins 0.000 description 2
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 2
- 101000970023 Homo sapiens NUAK family SNF1-like kinase 1 Proteins 0.000 description 2
- 101000988401 Homo sapiens PDZ and LIM domain protein 3 Proteins 0.000 description 2
- 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 description 2
- 101000583179 Homo sapiens Plakophilin-2 Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 206010021113 Hypothermia Diseases 0.000 description 2
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical class CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 2
- 108010052014 Liberase Proteins 0.000 description 2
- 206010024769 Local reaction Diseases 0.000 description 2
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 2
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 2
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical group [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102100021732 NUAK family SNF1-like kinase 1 Human genes 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102100029177 PDZ and LIM domain protein 3 Human genes 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- 206010034719 Personality change Diseases 0.000 description 2
- 206010034960 Photophobia Diseases 0.000 description 2
- 102100030348 Plakophilin-2 Human genes 0.000 description 2
- 208000002151 Pleural effusion Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 101001053942 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) Diphosphomevalonate decarboxylase Proteins 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- 206010047571 Visual impairment Diseases 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 208000012761 aggressive behavior Diseases 0.000 description 2
- 229960003805 amantadine Drugs 0.000 description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 2
- 229960000836 amitriptyline Drugs 0.000 description 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 239000004019 antithrombin Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000009739 binding Methods 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000036471 bradycardia Effects 0.000 description 2
- 208000006218 bradycardia Diseases 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 229960002802 bromocriptine Drugs 0.000 description 2
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229940046731 calcineurin inhibitors Drugs 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 2
- 230000011748 cell maturation Effects 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 230000002648 chondrogenic effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 239000012649 demethylating agent Substances 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000008472 epithelial growth Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000004880 explosion Methods 0.000 description 2
- 208000010771 expressive aphasia Diseases 0.000 description 2
- 230000004424 eye movement Effects 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000010370 hearing loss Effects 0.000 description 2
- 231100000888 hearing loss Toxicity 0.000 description 2
- 208000016354 hearing loss disease Diseases 0.000 description 2
- 229940006607 hirudin Drugs 0.000 description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000002631 hypothermal effect Effects 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 229940125721 immunosuppressive agent Drugs 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 208000022119 inability to concentrate Diseases 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000003447 ipsilateral effect Effects 0.000 description 2
- 210000000867 larynx Anatomy 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 231100000864 loss of vision Toxicity 0.000 description 2
- 208000018769 loss of vision Diseases 0.000 description 2
- 238000009593 lumbar puncture Methods 0.000 description 2
- 210000004705 lumbosacral region Anatomy 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 229960001344 methylphenidate Drugs 0.000 description 2
- 229960000334 methylprednisolone sodium succinate Drugs 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229960004866 mycophenolate mofetil Drugs 0.000 description 2
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 2
- 210000000276 neural tube Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 230000002188 osteogenic effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000000059 patterning Methods 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 208000026759 receptive aphasia Diseases 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 230000036362 sensorimotor function Effects 0.000 description 2
- 230000008786 sensory perception of smell Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- KYITYFHKDODNCQ-UHFFFAOYSA-M sodium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [Na+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 KYITYFHKDODNCQ-UHFFFAOYSA-M 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000007103 stamina Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000002820 sympathetic nervous system Anatomy 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- 230000007998 vessel formation Effects 0.000 description 2
- 230000009278 visceral effect Effects 0.000 description 2
- 208000029257 vision disease Diseases 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Chemical class 0.000 description 2
- 229960002647 warfarin sodium Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- CHADEQDQBURGHL-UHFFFAOYSA-N (6'-acetyloxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 CHADEQDQBURGHL-UHFFFAOYSA-N 0.000 description 1
- 125000001989 1,3-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([H])C([*:2])=C1[H] 0.000 description 1
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 1
- JCAULFRGWRHHIG-UHFFFAOYSA-N 1-bromo-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-henicosafluorodecane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br JCAULFRGWRHHIG-UHFFFAOYSA-N 0.000 description 1
- GXVUZYLYWKWJIM-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanamine Chemical compound NCCOCCN GXVUZYLYWKWJIM-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- VNDNKFJKUBLYQB-UHFFFAOYSA-N 2-(4-amino-6-chloro-5-oxohexyl)guanidine Chemical compound ClCC(=O)C(N)CCCN=C(N)N VNDNKFJKUBLYQB-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- XTOKHGASSRJDQX-UHFFFAOYSA-N 3-(1h-indol-3-yl)-4-(pentylamino)pyrrole-2,5-dione Chemical compound O=C1NC(=O)C(NCCCCC)=C1C1=CNC2=CC=CC=C12 XTOKHGASSRJDQX-UHFFFAOYSA-N 0.000 description 1
- RXMUPNVSYKGKMY-UHFFFAOYSA-N 3-amino-6-chloro-n-(diaminomethylidene)-5-(dimethylamino)pyrazine-2-carboxamide Chemical compound CN(C)C1=NC(N)=C(C(=O)N=C(N)N)N=C1Cl RXMUPNVSYKGKMY-UHFFFAOYSA-N 0.000 description 1
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
- RQQJJXVETXFINY-UHFFFAOYSA-N 5-(N,N-hexamethylene)amiloride Chemical compound N1=C(N)C(C(=O)N=C(N)N)=NC(Cl)=C1N1CCCCCC1 RQQJJXVETXFINY-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 208000010470 Ageusia Diseases 0.000 description 1
- 229910000497 Amalgam Inorganic materials 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 102000008076 Angiogenic Proteins Human genes 0.000 description 1
- 108010074415 Angiogenic Proteins Proteins 0.000 description 1
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 description 1
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000025978 Athletic injury Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010065417 Brachial plexopathy Diseases 0.000 description 1
- 206010006491 Brown-Sequard syndrome Diseases 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 1
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 1
- 108700012434 CCL3 Proteins 0.000 description 1
- 208000011597 CGF1 Diseases 0.000 description 1
- 101150093802 CXCL1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940123169 Caspase inhibitor Drugs 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 102000000013 Chemokine CCL3 Human genes 0.000 description 1
- 108010023736 Chondroitinases and Chondroitin Lyases Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 206010009696 Clumsiness Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010010301 Confusion and disorientation Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010011971 Decreased interest Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000000202 Diffuse Axonal Injury Diseases 0.000 description 1
- 101100460117 Drosophila melanogaster ND-23 gene Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 101150099168 Erap1 gene Proteins 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 102100031690 Erythroid transcription factor Human genes 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 206010015829 Extraocular muscle paresis Diseases 0.000 description 1
- 102000016970 Follistatin Human genes 0.000 description 1
- 108010014612 Follistatin Proteins 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 108010001498 Galectin 1 Proteins 0.000 description 1
- 102100021736 Galectin-1 Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 241000193159 Hathewaya histolytica Species 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 description 1
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 1
- 101000898718 Homo sapiens Endoplasmic reticulum aminopeptidase 2 Proteins 0.000 description 1
- 101001066268 Homo sapiens Erythroid transcription factor Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021138 Hypovolaemic shock Diseases 0.000 description 1
- 229940124790 IL-6 inhibitor Drugs 0.000 description 1
- 206010061213 Iatrogenic injury Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
- 239000012825 JNK inhibitor Substances 0.000 description 1
- 108010066327 Keratin-18 Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical class SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 1
- 206010051602 Laziness Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 102100031688 N-acetylgalactosamine-6-sulfatase Human genes 0.000 description 1
- 238000011789 NOD SCID mouse Methods 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 108010077641 Nogo Proteins Proteins 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 229930195708 Penicillin V Natural products 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- VSWDORGPIHIGNW-UHFFFAOYSA-N Pyrrolidine dithiocarbamic acid Chemical compound SC(=S)N1CCCC1 VSWDORGPIHIGNW-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100029831 Reticulon-4 Human genes 0.000 description 1
- 241000208422 Rhododendron Species 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000029033 Spinal Cord disease Diseases 0.000 description 1
- 208000020339 Spinal injury Diseases 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 230000029662 T-helper 1 type immune response Effects 0.000 description 1
- 230000030429 T-helper 17 type immune response Effects 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- 108090001109 Thermolysin Proteins 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 1
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 1
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 1
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960001456 adenosine triphosphate Drugs 0.000 description 1
- 230000002293 adipogenic effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000000947 anti-immunosuppressive effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000781 anti-lymphocytic effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000001494 anti-thymocyte effect Effects 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000000158 apoptosis inhibitor Substances 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 230000037424 autonomic function Effects 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 201000007623 brachial plexus lesion Diseases 0.000 description 1
- 208000021313 brachial plexus neuropathy from injury Diseases 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 206010007821 cauda equina syndrome Diseases 0.000 description 1
- 229960002129 cefixime Drugs 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical class COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 231100000870 cognitive problem Toxicity 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 229940041967 corticotropin-releasing hormone Drugs 0.000 description 1
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- DOBMPNYZJYQDGZ-UHFFFAOYSA-N dicoumarol Chemical compound C1=CC=CC2=C1OC(=O)C(CC=1C(OC3=CC=CC=C3C=1O)=O)=C2O DOBMPNYZJYQDGZ-UHFFFAOYSA-N 0.000 description 1
- 230000009521 diffuse axonal injury Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 108700006189 dopamine beta hydroxylase deficiency Proteins 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 210000004039 endoderm cell Anatomy 0.000 description 1
- 230000010595 endothelial cell migration Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- QDERNBXNXJCIQK-UHFFFAOYSA-N ethylisopropylamiloride Chemical compound CCN(C(C)C)C1=NC(N)=C(C(=O)N=C(N)N)N=C1Cl QDERNBXNXJCIQK-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 229960000556 fingolimod Drugs 0.000 description 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 239000002628 heparin derivative Substances 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000018883 loss of balance Diseases 0.000 description 1
- 210000005230 lumbar spinal cord Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 238000007898 magnetic cell sorting Methods 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 210000001872 metatarsal bone Anatomy 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 101710135378 pH 6 antigen Proteins 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940056367 penicillin v Drugs 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- WTWWXOGTJWMJHI-UHFFFAOYSA-N perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 description 1
- 229960001217 perflubron Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical class C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 239000002089 prostaglandin antagonist Substances 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000026416 response to pain Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
- 229950005741 rolipram Drugs 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000010332 selective attention Effects 0.000 description 1
- 230000021317 sensory perception Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 210000000323 shoulder joint Anatomy 0.000 description 1
- 229940115586 simulect Drugs 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 230000011273 social behavior Effects 0.000 description 1
- 230000004039 social cognition Effects 0.000 description 1
- 229940083618 sodium nitroprusside Drugs 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- 108010048090 soybean lectin Proteins 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 208000005801 spondylosis Diseases 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000023895 stem cell maintenance Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- XYKWNRUXCOIMFZ-UHFFFAOYSA-N tepoxalin Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC(=O)N(C)O)=N1 XYKWNRUXCOIMFZ-UHFFFAOYSA-N 0.000 description 1
- 201000006361 tethered spinal cord syndrome Diseases 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 229960005342 tranilast Drugs 0.000 description 1
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 description 1
- 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 239000011719 vitamin A Chemical class 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Pregnancy & Childbirth (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020217026195A KR20210107144A (ko) | 2010-12-17 | 2011-12-15 | 태반 줄기 세포를 이용하는 척수 손상 및 외상성 뇌 손상의 치료 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061424559P | 2010-12-17 | 2010-12-17 | |
| US61/424,559 | 2010-12-17 | ||
| PCT/US2011/065170 WO2012083024A1 (en) | 2010-12-17 | 2011-12-15 | Treatment of spinal cord injury and traumatic brain injury using placental stem cells |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197021890A Division KR20190090882A (ko) | 2010-12-17 | 2011-12-15 | 태반 줄기 세포를 이용하는 척수 손상 및 외상성 뇌 손상의 치료 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217026195A Division KR20210107144A (ko) | 2010-12-17 | 2011-12-15 | 태반 줄기 세포를 이용하는 척수 손상 및 외상성 뇌 손상의 치료 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20200116546A true KR20200116546A (ko) | 2020-10-12 |
Family
ID=46234728
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207027962A Ceased KR20200116546A (ko) | 2010-12-17 | 2011-12-15 | 태반 줄기 세포를 이용하는 척수 손상 및 외상성 뇌 손상의 치료 |
| KR1020137018583A Ceased KR20130128437A (ko) | 2010-12-17 | 2011-12-15 | 태반 줄기 세포를 이용하는 척수 손상 및 외상성 뇌 손상의 치료 |
| KR1020187024573A Ceased KR20180100251A (ko) | 2010-12-17 | 2011-12-15 | 태반 줄기 세포를 이용하는 척수 손상 및 외상성 뇌 손상의 치료 |
| KR1020227023531A Ceased KR20220103812A (ko) | 2010-12-17 | 2011-12-15 | 태반 줄기 세포를 이용하는 척수 손상 및 외상성 뇌 손상의 치료 |
| KR1020217026195A Ceased KR20210107144A (ko) | 2010-12-17 | 2011-12-15 | 태반 줄기 세포를 이용하는 척수 손상 및 외상성 뇌 손상의 치료 |
| KR1020237025647A Ceased KR20230116964A (ko) | 2010-12-17 | 2011-12-15 | 태반 줄기 세포를 이용하는 척수 손상 및 외상성 뇌손상의 치료 |
| KR1020197021890A Ceased KR20190090882A (ko) | 2010-12-17 | 2011-12-15 | 태반 줄기 세포를 이용하는 척수 손상 및 외상성 뇌 손상의 치료 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137018583A Ceased KR20130128437A (ko) | 2010-12-17 | 2011-12-15 | 태반 줄기 세포를 이용하는 척수 손상 및 외상성 뇌 손상의 치료 |
| KR1020187024573A Ceased KR20180100251A (ko) | 2010-12-17 | 2011-12-15 | 태반 줄기 세포를 이용하는 척수 손상 및 외상성 뇌 손상의 치료 |
| KR1020227023531A Ceased KR20220103812A (ko) | 2010-12-17 | 2011-12-15 | 태반 줄기 세포를 이용하는 척수 손상 및 외상성 뇌 손상의 치료 |
| KR1020217026195A Ceased KR20210107144A (ko) | 2010-12-17 | 2011-12-15 | 태반 줄기 세포를 이용하는 척수 손상 및 외상성 뇌 손상의 치료 |
| KR1020237025647A Ceased KR20230116964A (ko) | 2010-12-17 | 2011-12-15 | 태반 줄기 세포를 이용하는 척수 손상 및 외상성 뇌손상의 치료 |
| KR1020197021890A Ceased KR20190090882A (ko) | 2010-12-17 | 2011-12-15 | 태반 줄기 세포를 이용하는 척수 손상 및 외상성 뇌 손상의 치료 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20120156230A1 (enExample) |
| EP (1) | EP2651451A4 (enExample) |
| JP (1) | JP2014507390A (enExample) |
| KR (7) | KR20200116546A (enExample) |
| CN (1) | CN103501822A (enExample) |
| AU (1) | AU2011343739A1 (enExample) |
| CA (1) | CA2821818A1 (enExample) |
| MX (1) | MX2013006595A (enExample) |
| WO (1) | WO2012083024A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6204976B2 (ja) * | 2012-05-16 | 2017-09-27 | ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ | 多能性幹細胞由来の細胞培養物からニューロンを単離するための細胞表面特性 |
| JP2015521630A (ja) * | 2012-06-26 | 2015-07-30 | ラスティー プロパティー ホールディングス プロプライエタリー リミテッド | 頭痛の頻度および／または重症度を下げるための組成物および方法 |
| WO2014022427A1 (en) * | 2012-08-02 | 2014-02-06 | Bioaxone Biosciences Inc. | Inhibition of rho and or rock and cell transplantation |
| EP2994147A4 (en) * | 2013-05-10 | 2017-03-08 | Cell-Innovations IP Pty Ltd | Compositions and methods for the treatment of tinnitus |
| WO2015023901A1 (en) * | 2013-08-15 | 2015-02-19 | The Regents Of The University Of California | Placenta-derived multipotent stem cells |
| DK3157548T3 (da) | 2014-06-18 | 2021-09-06 | Csl Behring Gmbh | Terapi anvendelse af en faktor xii-inhibitor i en neurotraumatisk sygdom |
| US10493105B2 (en) * | 2014-09-11 | 2019-12-03 | Taiwan Mitochondrion Applied Technology Co., Ltd | Isolated adipose-derived mesenchymal stem cells treated with angelica extract or butylidenephthalide, and wherein the cells have an increased mitochondrial membrane potential and a decreased level of IL-8, and methods for treating parkinson's disease |
| GB201518263D0 (en) * | 2015-10-15 | 2015-12-02 | Oxford Bioelectronics Ltd | Method |
| EP3423070B1 (en) * | 2016-03-03 | 2022-05-04 | Henry Ford Health System | 3-d collagen scaffold-generated exosomes and uses thereof |
| EA201991371A1 (ru) * | 2016-12-05 | 2019-12-30 | Селулэрити, Инк. | Лечение лимфедемы и связанных состояний с использованием плацентарных адгезивных клеток |
| WO2018198012A1 (en) * | 2017-04-24 | 2018-11-01 | Pluristem Ltd. | Methods and compositions for treating neurological disorders |
| US20180322956A1 (en) * | 2017-05-05 | 2018-11-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Time Window-Based Platform for the Rapid Stratification of Blunt Trauma Patients into Distinct Outcome Cohorts |
| WO2018222723A1 (en) | 2017-05-30 | 2018-12-06 | Vertex Pharmaceuticals Incorporated | C3 fusion protein and methods of making and using thereof |
| CN107227521B (zh) * | 2017-08-09 | 2023-03-14 | 青岛金汇丰机械有限公司 | 一种五轴毛纺粗纱机 |
| KR20190048894A (ko) | 2017-10-31 | 2019-05-09 | 경상대학교산학협력단 | Jnk 활성 억제제를 유효성분으로 포함하는 퇴행성 신경질환의 예방 또는 치료용 약학적 조성물 |
| CN108413478A (zh) * | 2018-02-11 | 2018-08-17 | 广东美的环境电器制造有限公司 | 一种控制方法、装置及计算机可读存储介质 |
| KR102070403B1 (ko) | 2019-09-06 | 2020-01-28 | 경상대학교 산학협력단 | Jnk 활성 억제제를 유효성분으로 포함하는 외상성 뇌손상의 치료용 약학적 조성물 |
| CN114561355B (zh) * | 2022-01-23 | 2023-04-11 | 四川大学华西医院 | 一种脊髓瘢痕组织细胞急性快速分离方法 |
| CN117274869B (zh) * | 2023-09-25 | 2024-03-26 | 北方工业大学 | 一种基于形变场提取的细胞形变动态分类方法及系统 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7311905B2 (en) * | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
| US20080152629A1 (en) * | 2000-12-06 | 2008-06-26 | James Edinger | Placental stem cell populations |
| KR20180105266A (ko) * | 2005-12-29 | 2018-09-27 | 안트로제네시스 코포레이션 | 태반 줄기 세포 집단 |
| US20120269774A1 (en) * | 2006-09-21 | 2012-10-25 | Medistem Laboratories, Inc | Allogeneic stem cell transplants in non-conditioned recipients |
| CN103356710A (zh) * | 2007-02-12 | 2013-10-23 | 人类起源公司 | 利用胎盘干细胞治疗炎性疾病 |
| US20090214484A1 (en) * | 2008-02-22 | 2009-08-27 | Nikolay Mironov | Stem cell therapy for the treatment of central nervous system disorders |
| CA2734237C (en) * | 2008-08-20 | 2019-07-02 | Anthrogenesis Corporation | Treatment of stroke using isolated placental cells |
| WO2010059828A1 (en) * | 2008-11-19 | 2010-05-27 | Anthrogenesis Corporation | Amnion derived adherent cells |
-
2011
- 2011-12-15 KR KR1020207027962A patent/KR20200116546A/ko not_active Ceased
- 2011-12-15 CN CN201180067894.0A patent/CN103501822A/zh active Pending
- 2011-12-15 KR KR1020137018583A patent/KR20130128437A/ko not_active Ceased
- 2011-12-15 EP EP11848627.3A patent/EP2651451A4/en not_active Withdrawn
- 2011-12-15 KR KR1020187024573A patent/KR20180100251A/ko not_active Ceased
- 2011-12-15 KR KR1020227023531A patent/KR20220103812A/ko not_active Ceased
- 2011-12-15 KR KR1020217026195A patent/KR20210107144A/ko not_active Ceased
- 2011-12-15 KR KR1020237025647A patent/KR20230116964A/ko not_active Ceased
- 2011-12-15 AU AU2011343739A patent/AU2011343739A1/en not_active Abandoned
- 2011-12-15 MX MX2013006595A patent/MX2013006595A/es unknown
- 2011-12-15 WO PCT/US2011/065170 patent/WO2012083024A1/en not_active Ceased
- 2011-12-15 KR KR1020197021890A patent/KR20190090882A/ko not_active Ceased
- 2011-12-15 CA CA2821818A patent/CA2821818A1/en not_active Abandoned
- 2011-12-15 US US13/327,245 patent/US20120156230A1/en not_active Abandoned
- 2011-12-15 JP JP2013544781A patent/JP2014507390A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012083024A1 (en) | 2012-06-21 |
| KR20230116964A (ko) | 2023-08-04 |
| KR20130128437A (ko) | 2013-11-26 |
| MX2013006595A (es) | 2014-04-07 |
| KR20180100251A (ko) | 2018-09-07 |
| JP2014507390A (ja) | 2014-03-27 |
| KR20190090882A (ko) | 2019-08-02 |
| KR20210107144A (ko) | 2021-08-31 |
| CA2821818A1 (en) | 2012-06-21 |
| CN103501822A (zh) | 2014-01-08 |
| US20120156230A1 (en) | 2012-06-21 |
| AU2011343739A1 (en) | 2013-05-02 |
| KR20220103812A (ko) | 2022-07-22 |
| EP2651451A1 (en) | 2013-10-23 |
| EP2651451A4 (en) | 2014-05-21 |
| WO2012083024A8 (en) | 2013-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20120156230A1 (en) | Treatment of spinal cord injury and traumatic brain injury using placental stem cells | |
| US11090339B2 (en) | Treatment of pain using placental stem cells | |
| US8071376B2 (en) | Production of oligodendrocytes from placenta-derived stem cells | |
| EP2329012B1 (en) | Treatment of stroke using isolated placental cells | |
| US20120201787A1 (en) | Treatment of spinal cord injury and traumatic brain injury using amnion derived adherent cells | |
| KR20200047797A (ko) | 태반 줄기 세포를 사용한 혈관신생 | |
| KR20130092394A (ko) | 태반 줄기 세포를 사용한 사르코이드증의 치료 | |
| US20230302058A1 (en) | Treatment of lymphedema and related conditions using placental adherent cells | |
| HK1162600A (en) | Production of oligodendrocytes from placenta-derived stem cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20200928 Application number text: 1020197021890 Filing date: 20190725 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20201027 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20201102 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20210518 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20201102 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |